On Thursday, Eli Lilly and Co. (NYSE:LLY) reported positive topline results from its Phase 3 ACHIEVE-4 trial of its oral drug Foundayo (orforglipron) for weight loss.

The study showed that orforglipron met the primary goal of cardiovascular safety compared with insulin glargine in adults with type 2 diabetes and obesity or overweight at elevated cardiovascular risk.

The study also indicated stronger reductions in blood sugar and body weight, positioning the therapy as a potential alternative to insulin-based treatment.

Foundayo Meets Cardiovascular Safety Goal

The ACHIEVE-4 trial, the largest and longest study of Foundayo in type 2 diabetes so far, enrolled more than 2,700 participants across 15 countries.

The drug demonstrated a non-inferior risk of major adverse cardiovascular events (MACE-4), including cardiovascular death, heart attack, stroke, and hospitalization for unstable chest pain, compared with insulin glargine.

The risk of these events was 16% lower with Foundayo, with a hazard ratio of 0.84, meeting predefined criteria for non-inferiority.